A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Condition: Muscle-Invasive Bladder Carcinoma Intervention: Drug: AMVAC + Nivolumab Sponsor: Fox Chase Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Neoadjuvant Therapy | Research | Study